Fresenius | FRE - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Akzo Nobel EUR 936M 102M 2025-12
Alcon AG USD 1.69B 175M 2026-03
AstraZeneca USD 12.61B 225M 2026-03
BASF EUR 3.11B 55M 2025-12
Bayer EUR 6.94B 1.58B 2025-12
Beiersdorf EUR 1.54B 1.16B 2025-06
DaVita Healthcare Partners USD 895.46M 128.1M 2026-03
Demant DKK 8.82B 277M 2025-12
E.ON EUR 5.41B 672M 2026-03
Essilor EUR 8.3B 547M 2025-12
Fresenius EUR 1.51B 214M 2025-12
Fresenius Medical Care EUR 1.18B 210M 2026-03
Getinge SEK 5.05B 1.5B 2024-12
Givaudan CHF 1.55B 140M 2025-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
GN Store Nord DKK 2.5B 344M 2025-12
GRIFOLS EUR 686.84M 56.95M 2025-12
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
Lonza CHF 1.29B 248M 2025-06
Merck EUR 3.07B 104M 2026-03
Novartis USD 10.07B 184M 2026-03
Philips EUR 1.77B 522M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
RWE EUR 2.74B 2.02B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Smith & Nephew USD 2.09B 117M 2025-12